Fecal calprotectin is a protein used as a diagnostic marker for inflammatory bowel diseases. We determined upper limits for normal calprotectin values for neonatal, 6, 12 and 24 months old children using a turbidimetric immunoassay in a cohort of Swedish children. The advantage of the method is that, opposite to previously used ELISA method, it enables measuring single samples, and thus, shortens the analysis times significantly. There were 72 samples (41.7 % female) collected neonatally, 63 samples (34.9 % female) at 6 months, 60 samples 
Introduction
Abdominal pain is one of the most common causes for seeking medical help during childhood and is reported to affect 10% to 20% of schoolchildren at an extent that interferes with normal daily activity [1, 2] . Abdominal pain and diarrhea are both frequently observed in functional gastrointestinal disorders in children, but it may also be the first sign of an inflammatory bowel disease (IBD), which has become more common among children during the last decades [3, 4] . For long, histopathological analysis of biopsies taken during endoscopy were considered the gold standard for diagnosing IBD, but as this is an invasive and costly procedure, especially with pediatric patients, non-invasive diagnostic tools are sought. New promising markers for diagnostic purposes have been suggested, including measurement of the inflammatory marker calprotectin, which can be analyzed in fecal samples. While fecal calprotectin alone is not sufficient for the initial diagnosis of IBD, it is now considered a reliable marker for active IBD in adults [5] and has been suggested to replace biopsies to predict early relapse of IBD [6] . It has also recently been suggested for the triage of pediatric patients with symptoms suggestive of IBD [7] and can be used as a rule-out test for IBD [8] .
Further, detecting abnormal calprotectin levels in infancy could also be used for other diagnostic purposes. For example, high calprotectin values have been linked to the development of other immune-mediated diseases, such as atopic dermatitis and asthma [9] . Further, higher fecal calprotectin levels have been found in children with bacterial gastroenteritis compared to children with viral disease [10] .
Calprotectin is a calcium and zinc-binding protein consisting of two heavy and one light polypeptide chains. It is abundant in neutrophils, where it can constitute up to 60 % of the total cytostolic protein content [11] , but it is also present in monocytes and macrophages [12] . The protein can be measured in feces, plasma, and other body fluids. In feces it has a homogeneous distribution and is stable for up to 7 days at room temperature [13] , making it an ideal diagnostic marker. However, constraints related to sample analysis have hampered the use of calprotectin, as samples were run in batches in 96 well plates using enzyme linked immunosorbent assay (ELISA) and filling the batch can take a long time. A new method based on particle enhanced turbidimetric immunoassay (PETIA), is available, allowing rapid identification of calprotectin in single fecal samples, enabling fast analysis [14] . The results obtained with this test are comparable to the previously used ELISA method [14] .
However, in order to use fecal calprotectin in clinical practice, it is essential to know the upper limit of normal variation among healthy individuals. Such normal values have not been established for the turbidimetric immunoassay. Here we report upper limits for normal values of calprotectin in feces based on a cohort of infants whose calprotectin levels were measured at birth and at the age of 6, 12 and 24 months.
Materials and Methods

The Born into Life Study
The infants included into this study participated in the Born into Life study (Smew et al., submitted), which is a longitudinal cohort study consisting of two cohorts -one of mothers, and the other of their children. The mothers were originally recruited into a larger prospective cohort study LifeGene [15] , which consists of index people between 18 to 45 years of age. Female study participants in LifeGene who became pregnant were recruited into Born into Life and answered questionnaires regarding pregnancy, health status and lifestyle at baseline and twice during pregnancy. After gaining parental informed consent, the children were included in the birth cohort upon delivery and all were delivered at the same clinic. Only healthy, full term infants were included in the study. These children were followed with parental questionnaires and biological samples were collected at birth and at 6, 12 and 24 months of age ( Table 1) .
The health status of the children in the cohort represents well the general population of young children in Sweden in regards to occurrence of food allergies [16] and eczema [17] , as well as for antibiotics use [18] . Also the frequency of hospital visits reflects the general population of young children in Sweden [19] . [ Table 1 at 248 µg/g and 0.6% at 1392 µg/g. The fecal calprotectin PETIA shows a good agreement with the Bühlmann ELISA [14] , which in external quality assurance programs belongs to a group of manufacturers that has a calibration above the median in quality assurance programs [20] .
Statistical Analyses
As the reliable detection limit for calprotectin with the turbidimetric method is around project.org/package=referenceIntervals). Outliers were detected using Horn´s method [21] . Correlation in calprotectin concentration across time was tested using Spearman correlation and the impact of gender to calprotectin levels was tested with t-test. The variation among age groups was tested using Kruskal-Wallis one-way analysis of variance with posthoc test after Nemenyi using R-Package PMCMR (http://CRAN.Rproject.org/package=PMCMR). The results were considered significant at P < 0.05. All calculations were performed using R (http://www.Rproject.org).
Results
The data include 246 evaluations for 84 individuals across 4 different time points. Table 2 .
[ Table 2 and Figure 1 near here]
Discussion
Our main purpose of the study was to set upper limits for normal variation in fecal calprotectin values during the two first years of life, enabling the use of PETIA as a diagnostic tool. These results confirm that the values are very high in newborns [22, 23] , but then decrease fast, apparently stabilizing already at the age of one year. Both diet and the frequency of gastrointestinal infections vary between countries [28] , thus, it is important that the reference material is similar to the patient population that the assay will be used for. Here, the pediatric study population was recruited in Sweden and is considered representative for Caucasians living in the northern part of Europe.
The main application for fecal calprotectin in adults is to distinguish between irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD). As an inexpensive noninvasive assay fecal calprotectin can be used more frequently, allowing a closer treatment monitoring than with colonoscopy. It can thus be used to monitor the effects of different diets on the inflammatory activity [20] . In children, there is also another possible application. A previous study has indicated that fecal calprotectin could be used as a tool for distinguishing between viral and bacterial gastroenteritis with a specificity of 88.9%, and specificity of 76.0% for a cut-off of 710 mg/l [10] .
Another large study found strong associations of calprotectin with viral/bacterial diagnosis and also found that the levels of calprotectin were associated with more severe disease in children with more severe gastroenteritis in both the bacterial and viral group separately [29] . However, a third study in 50 children showed no additional benefit of measuring fecal calprotectin above CRP measurement for the discrimination of viral to bacterial gastroenteritis [30] . Further, larger validation studies are needed on this issue, and if shown predictive, rapid determination of fecal calprotectin with normal values would be needed before implementation into the clinical setting.
The limitation of this study is that the number of participants was low. This could impact, for example, the variation within values. For example, one of the values at six months was very high (> 1000 µg mg -1 ), but due to the small sample size we do not know whether such high values are regularly detected in young healthy infants.
To conclude, determining the upper limits for normal values enables the use of the turbidimetric immunoassay as a diagnostic tool for gastrointestinal disorders in children under 2 years, facilitating fast and cost efficient monitoring of gastric inflammation.
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